January 10, 2023 - A significant milestone to bring in the new year, the FDA approved Wegovy (semaglutide) on Dec.

3 days ago - The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs that has revolutionized obesity treatment.

3 days ago - Dec 22 (Reuters) - The U.S. Food and Drug Administration approved Novo Nordisk's (NOVOb.CO), opens new tab weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as ...

3 days ago - It remains the only oral glucagon-like peptide-1 (GLP-1) receptor agonist that has achieved FDA approval.

Return to Article Details Semaglutide (Wegovy)

3 days ago - Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026 · Bagsværd, Denmark, 22 December 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral ...

June 14, 2024 - Semaglutide is a GLP-1 agonist, as is a related agent, also from Novo Nordisk, liraglutide (Saxenda), a daily subcutaneous injection, which was approved for use in adolescents aged 12 and older in December 2020.

4 days ago - The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to access a highly effective treatment.

November 11, 2025 - FDA Approved: Yes (First approved June 4, 2021) Brand name: Wegovy Generic name: semaglutide Dosage form: Injection Company: Novo Nordisk Treatment for: Weight Loss (Obesity/Overweight), Cardiovascular Risk Reduction, Nonalcoholic Steatohepatitis

4 days ago - We are prepared for a full US launch in early January 2026, with manufacturing well underway in our North Carolina facilities." The FDA approval of Wegovy® pill is based on the results from the OASIS 4 phase 3 clinical trial, which was a 64-week ...

2 weeks ago - NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.

1 month ago - Wegovy directly competes with Eli Lilly’s tirzepatide medicine Zepbound. Like Novo Nordisk, LLY also generates a substantial portion of its revenues from sales of this drug. NVO and LLY are racing to introduce oral weight-loss pills. Novo Nordisk has already submitted a regulatory filing with the FDA seeking approval for an oral version of Wegovy, with a final decision expected before this year’s end.

1 month ago - View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-a-higher-dose-of-wegovy-injection-7-2-mg-302626162.html

2 days ago - In January 2023, the US FDA prescription label for Rybelsus was updated to reflect that it can be used as a first-line treatment for adults with type 2 diabetes. In June 2021, a higher-dose version for injectable use, sold under the brand name Wegovy, was approved by the FDA as an anti-obesity ...

3 weeks ago - Thanks to the voucher, Novo should see the FDA's decision within one to two months. If approved in that timeframe, the nod could come in around the same time as the FDA’s expected fourth-quarter decision on Novo’s 25 mg oral semaglutide, ...

1 month ago - The new, higher dose of Wegovy® (semaglutide 7.2 mg) is currently under review with the European Medicines Agency (EMA), in the UK and several other countries.

3 days ago - Novo Nordisk's obesity pill was approved first. It has the same ingredient — semaglutide — that's in Wegovy, Ozempic and also in Rybelsus, the company's Type 2 diabetes pill that was approved in 2019.

November 13, 2025 - Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025.